Urology Times

Subgroup analysis evaluates darolutamide in previously treated mCRPC

by

Darolutamide (Nubeqa) demonstrated modest antitumor activity in molecularly defined subgroups of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors (ARPIs), according to findings from the phase 2 CCTG IND.234: PC_BETS trial presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.1 “Darolutamide is structurally distinct … Read more

Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

by

Adjuvant treatment with pembrolizumab (Keytruda) continued to show consistent overall survival (OS) and disease-free survival (DFS) benefits compared with placebo for patients with clear cell renal cell carcinoma (ccRCC), according to a landmark 5-year analysis of the phase 3 KEYNOTE-564 study (NCT03142334) presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, … Read more

Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy

by

While the rate of ureteral strictures following ureteroscopic laser lithotripsy is low, the incidence was nearly doubled when using a thulium fiber laser (TFL) vs a holmium laser, according to data presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. In an interview with Urology Times®, lead author Amir S. … Read more

SBRT may offer a safe alternative to CFRT after prostatectomy

by

Stereotactic body radiotherapy appears safe and demonstrated comparable patient-reported outcomes through 2 years compared with conventionally fractionated radiotherapy (CFRT) in men with a rising prostate-specific antigen (PSA) level after radical prostatectomy, according to data from a phase 2 SCIMITAR trial (NCT03541850) published in JAMA Oncology.1 “This approach could remove a major barrier to post-surgery radiation … Read more

Laura Davis, MD, on link between microplastics and bladder cancer

by

Data presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada suggest a link between plastics-processing waste release and bladder cancer incidence. In an interview with Urology Times®, co-author Laura E. Davis, MD, shares key insights on the study’s background and findings. “We all know that there’s a component of environmental … Read more

Physical function and frailty measures offer distinct insights in patients with bladder cancer

by

An interim analysis of the UW Bounceback Study showed that baseline physical function was not associated with self-reported frailty assessments in older patients with bladder cancer who are undergoing radical cystectomy.1 Data did show a significant association between CARE-FI assessment scores and length of stay. According to the authors, led by Jordan Sheldon of the … Read more

Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025

by

The 40th Annual European Association of Urology Congress in Madrid, Spain, featured an extensive scientific program. In a recent video for Urology Times®, Betty Wang, MD, provided insight on 3 presentations that she believes “may be game changing” in urology. The first study Wang highlighted was “Micro-ultrasound-guided versus MRI-guided biopsy for prostate cancer diagnosis: The … Read more

Implications for urologists, prescribers, and patients

by

In February 2025, the labeling requirements for testosterone caught up with what urologists and other prescribers have known for years: testosterone does not increase the risk of adverse cardiovascular outcomes.1 The journey to this conclusion began in 2014, when the FDA first convened a Joint Meeting of the Bone, Reproductive and Urologic Drugs and the … Read more

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

by

Both isodose and dose-escalated moderately hypofractionated radiotherapy (MHFRT) showed comparable efficacy to conventionally-fractionated radiotherapy (CFRT) in patients with prostate cancer, though dose-escalated MHFRT was associated with greater odds of bowel toxicity, according to data from a recent meta-analysis published in Lancet Oncology.1 The study assessed outcomes from 7 phase 3 trials. With isodose MHFRT, there … Read more